Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 9 · newest first

  1. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular MedicineThrombosis and Haemostasis · 2020
  2. The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic ReviewFrontiers in Oncology · 2020
  3. Emerging drugs for the treatment of Waldenström macroglobulinemiaExpert Opinion on Emerging Drugs · 2020
  4. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseLeukemia · 2020
  5. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 studyBlood Cancer Journal · 2020
  6. Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significanceBritish Journal of Haematology · 2020
  7. Next generation flow cytometry for MRD detection in patients with AL amyloidosisAmyloid · 2020
  8. The emerging role of BET inhibitors in breast cancerThe Breast · 2020
  9. Systemic AL Amyloidosis: Current Approaches to Diagnosis and ManagementHemaSphere · 2020
  10. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyBlood · 2020
  11. Bortezomib, Melphalan, and Dexamethasone for Light-Chain AmyloidosisJournal of Clinical Oncology · 2020
  12. Predictors of adverse prognosis in COVID‐19: A systematic review and meta‐analysisEuropean Journal of Clinical Investigation · 2020
  13. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosisAmyloid · 2020
  14. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor CarfilzomibInternational Journal of Molecular Sciences · 2020
  15. Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple MyelomaCancers · 2020
  16. The current role of BTK inhibitors in the treatment of Waldenstrom’s MacroglobulinemiaExpert Review of Anticancer Therapy · 2020
  17. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaAnnals of Hematology · 2020
  18. Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) TrialBritish Journal of Cancer · 2020
  19. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemicBritish Journal of Haematology · 2020
  20. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease ProgressionJournal of Clinical Oncology · 2020
  21. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysisLeukemia · 2020
  22. Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS SyndromeHemaSphere · 2020
  23. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaLeukemia · 2020
  24. Oncology during the COVID‑19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients (Review)Oncology Letters · 2020
  25. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyThe Lancet Haematology · 2020
  26. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaLeukemia · 2020
  27. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agentsBlood Cancer Journal · 2020
  28. Hematological findings and complications of COVID‐19American Journal of Hematology · 2020
  29. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaLeukemia & lymphoma/Leukemia and lymphoma · 2020
  30. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysisBlood Cancer Journal · 2020
  31. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRdExpert Review of Hematology · 2020
  32. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myelomaBlood Advances · 2020
  33. Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myelomaBlood Cancer Journal · 2020
  34. Clinical biomarkers directing the management of patients with colon and lung cancer (beyond oncogene-addicted NSCLC)Forum of Clinical Oncology · 2020
  35. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsLeukemia · 2020
  36. Comparison of efficacy from two different dosing regimens of bortezomib: an exposure–response analysisBritish Journal of Haematology · 2020
  37. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaBlood Cancer Journal · 2020
  38. Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco‐Israeli collaborative myeloma working groupAmerican Journal of Hematology · 2020
  39. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyLeukemia · 2020
  40. Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implicationsAmyloid · 2020
  41. Efficacy of Panobinostat for the Treatment of Multiple MyelomaJournal of Oncology · 2020
  42. Solid Organ Transplantation in AmyloidosisActa Haematologica · 2020
  43. Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trialEuropean Journal Of Haematology · 2019
  44. Prognostic role of microRNAs in breast cancer: A systematic reviewOncotarget · 2019
  45. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study designFuture Oncology · 2019
  46. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasoneBlood Advances · 2019
  47. Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)Blood · 2019
  48. Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had PlasmacytomasBlood · 2019
  49. Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myelomaExpert Review of Anticancer Therapy · 2019
  50. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trialsLeukemia & lymphoma/Leukemia and lymphoma · 2019